ClinicalTrials.gg
Not yet recruitingNCT07937891Updated Nov 16, 2026

The PRECISE-DIET Trial

An interventional study of Personalised dietary intervention and Standard dietary counselling in Type 2 Diabetes, Nutrition and Carbohydrate, sponsored by Steno Diabetes Center Copenhagen. Not yet recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Steno Diabetes Center Copenhagen · Not applicable, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 31 studies in Diabetes Mellitus, Type 2 by Steno Diabetes Center Copenhagen — 9 open to participants now, 10 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Steno Diabetes Center Copenhagen.

Planned enrollment
6th of 24
130 · median 94
Started
2027
the only one that year
No phase
17 of 31
6 open now
Registered
31st of 31
by date

Among the 31 studies in Diabetes Mellitus, Type 2 by Steno Diabetes Center Copenhagen, this one is the 6th largest by planned enrollment of the 24 interventional ones that give a count, is the only one that started in 2027, is one of 17 with no phase, and was the 31st registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

9 of the 31 studies in Diabetes Mellitus, Type 2 by Steno Diabetes Center Copenhagen are open now, in 2 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Diabetes Mellitus, Type 2 by Steno Diabetes Center Copenhagen, or all of them as a file.
02

Study summary

People with type 2 diabetes receive standard dietary advice to improve glycaemic control. However, blood glucose responses to the same foods can vary considerably between individuals. This randomised controlled trial aims to investigate whether personalised carbohydrate recommendations guided by continuous glucose monitoring (CGM) improve glycaemic control (HbA1c) compared with standard dietary care.

A total of 130 adults with type 2 diabetes will be randomly assigned to one of two groups. The study will include a 6-month intervention period followed by a 6-month follow-up period. The intervention group will receive dietitian-led personalised carbohydrate recommendations informed by CGM data, supplemented by group-based education in carbohydrate counting. The control group will receive standard individual dietary counselling provided by a dietitian without the use of CGM.

The primary outcome is the between-group difference in change in HbA1c from baseline to 6 months.

03

Conditions studied

  • Type 2 Diabetes
  • Nutrition
  • Carbohydrate

Keywords

  • Type 2 Diabetes; Precision Nutrition; Continuous Glucose Monitoring (CGM); Personalised Dietary Counselling; Carbohydrates
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • T2D
  • Diabetes duration of ≥12 months
  • Age ≥18 years
  • ≥58 mmol/mol
  • Attending the SDCC outpatient clinic
  • Provided voluntary signed

Exclusion criteria

Exclusion Criteria:

  • Inability to understand the study information
  • Medical complications that prevent lowering to below 58 mmol/mol
  • Use of insulin therapy
  • Low daily carbohydrate intake (defined as below 25 E% or 100 g/day) prior to study inclusion
  • Systematic use of
  • Using or requiring a specialised diet (e.g., protein restriction in kidney disease)
  • Circumstances that affect HbA1c (e.g., liver disease and anaemia)
  • Known or suspected drug or alcohol abuse
  • Pregnancy or breastfeeding or plans of pregnancy within the study period
  • Participation in other clinical trials
  • Individuals with a of \<27 kg/m²
  • Initiation of GLP-1 receptor agonist or SGLT inhibitor therapy within the previous 3 months
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
130 participants (estimated)

Study arms

  • Experimental
    Personalised dietary intervention

    CGM-supported personalised carbohydrate recommendations

    Behavioral: Personalised dietary intervention

  • Active comparator
    Standard dietary counselling

    Standard dietary counselling for type 2 diabetes

    Behavioral: Standard dietary counselling

Interventions

  • BehavioralPersonalised dietary intervention

    Participants will receive structured, personalised dietary recommendations supported by continuous glucose monitoring (CGM). Initial carbohydrate recommendations will be based on approximately 35% of total energy intake and translated into individual targets expressed as grams of carbohydrate per day and per meal. These targets will be adjusted throughout the intervention based on individual needs and glycaemic responses rather than prescribed as fixed amounts. CGM data will be used to assess individual postprandial glucose responses and guide adjustments to carbohydrate intake and its distribution throughout the day. The intervention will also include education in basic carbohydrate counting and dietitian-led counselling to support the implementation and maintenance of dietary changes.

  • BehavioralStandard dietary counselling

    Participants will receive standard dietary counselling for type 2 diabetes based on current dietary recommendations, without CGM-guided personalisation of carbohydrate intake. The counselling will include one initial 60-minute individual consultation with a dietitian, followed by two 30-minute follow-up consultations.

06

What researchers measure

Primary outcomes

  1. Change in HbA1c

    Between-group difference in change in HbA1c (mmol/mol) from baseline to 6 months

    Time frame: Baseline to 6 months

Secondary outcomes

  1. Change in HbA1c at 12 months

    Between-group difference in HbA1c change (mmol/mol)

    Time frame: Baseline to 12 weeks and 12 months

  2. Time in range (TIR)

    Percentage of CGM time with glucose 3.9-10.0 mmol/L

    Time frame: Baseline, 6 and 12 months

  3. Time above range (TAR)

    Percentage of CGM time with glucose \>10.0 mmol/L

    Time frame: Baseline, 6 and 12 months

  4. Time below range (TBR)

    Percentage of CGM time with glucose \<3.9 mmol/L

    Time frame: Baseline, 6 and 12 months

  5. Estimated HbA1c

    HbA1c estimated from CGM data (mmol/mol)

    Time frame: Baseline, 6 and 12 months

  6. Change in glycaemic variability

    Coefficient of variation (%) derived from CGM

    Time frame: Baseline, 6 and 12 months

  7. Body mass index (BMI)

    kg/m²

    Time frame: Baseline, 6 and 12 months

  8. Waist and hip circumference

    cm

    Time frame: Baseline, 6 and 12 months

  9. Blood pressure

    Systolic and diastolic (mmHg)

    Time frame: Baseline, 6 and 12 months

  10. plasma glucose

    mmol/L

    Time frame: Baseline, 6 and 12 months

  11. Plasma insulin

    pmol/L

    Time frame: Baseline, 6 and 12 months

  12. C-peptide

    pmol/L

    Time frame: Baseline, 6 and 12 months

  13. Total cholesterol

    mmol/L

    Time frame: Baseline, 6 and 12 months

  14. LDL cholesterol

    mmol/L

    Time frame: Baseline, 6 and 12 months

  15. HDL cholesterol

    mmol/L

    Time frame: Baseline, 6 and 12 months

  16. Triglycerides

    mmol/L

    Time frame: Baseline, 6 and 12 months

  17. Diabetes distress (questionnaire)

    Problem Areas in Diabetes (PAID) score

    Time frame: Baseline, 6 and 12 months

  18. Treatment satisfaction (questionnaire)

    Diabetes Treatment Satisfaction Questionnaire (DTSQ) score

    Time frame: Baseline, 6 and 12 months

Other outcomes

  1. Change in glucose-lowering medication

    Changes in type and dose of glucose-lowering medication

    Time frame: Baseline, 6 and 12 months

  2. Personality traits (questionnaire)

    Big Five Inventory (BFI-44) scores

    Time frame: Baseline

  3. Dietary intake

    Total energy intake and macronutrient composition from a 3-day food record

    Time frame: Baseline and 6 months

  4. Physical activity

    Physical activity level measured with an AX3 accelerometer worn for 7 days

    Time frame: Baseline and 6 months

  5. Carbohydrate estimation ability (questionnaire)

    Accuracy of participants' carbohydrate estimates

    Time frame: Baseline, 6 and 12 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2027; primary completion for Sep 2028, 19 months later.

Of 2,068 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 19 months is close to that.

Counting every sponsor, half of 2,245 studies reached it within 21 months; a quarter within 10 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 16, 2026
StartEst.
Feb 2027
Primary completionEst.
Sep 2028
CompletionEst.
Mar 2029
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07937891
Responsible party
Bettina Ewers (Head of Nutrition and Researcher, Steno Diabetes Center Copenhagen) — Principal investigator
First posted
Nov 16, 2026
Start date
Feb 2027 (estimated)
Primary completion
Sep 2028 (estimated)
Completion
Mar 2029 (estimated)
Last update
Nov 16, 2026

Study contacts

Zandra Overgaard Pedersen, MSc. Health Science
Contact
zandra.overgaard.pedersen@regionh.dk
24456114
Bettina Ewers, PhD
Contact
bettina.ewers@regionh.dk
30912997

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion